Arachnoiditis may be cause of severe chronic pain, study says | Study draws parallels between tinnitus, chronic pain | Inflammatory back pain may affect bone mineral density
September 30, 2015
News for the pain professional

Pain Research News
Arachnoiditis may be cause of severe chronic pain, study says
Patients who have chronic back pain with leg tremors and severe pain when standing for long periods may have have arachnoiditis, according to a study presented at the American Academy of Pain Management's annual meeting. Dr. Forest Tennant of the Veract Intractable Pain Clinic in California said arachnoiditis has been considered a rare condition, but may be underdiagnosed. Medscape (free registration) (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
Study draws parallels between tinnitus, chronic pain
A review published in Trends in Cognitive Sciences proposes that tinnitus and chronic pain may involve changes to what the authors call the brain's central gatekeeping system, involved in the control of sensory signals. Imaging has uncovered changes in the nucleus accumbens and the ventromedial prefrontal cortex in patients with tinnitus and those with chronic pain. Researcher Josef Rauschecker suggested both conditions involve meaningless signaling that the brain is unable to filter out. (9/23)
Share: LinkedInTwitterFacebookGoogle+Email
Inflammatory back pain may affect bone mineral density
Research said more than 40% of patients with inflammatory back pain indicative of early axial spondyloarthritis saw declines in bone mineral density over two years. The study in the journal Rheumatology found anti-tumor necrosis factor treatment was linked with positive changes in bone mineral density in the lumbar spine and hip regions. Patients taking nonsteroidal anti-inflammatory drugs who gained body mass had increased protection in the hip. MedPage Today (free registration) (9/26)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
Treatment News
FDA grants priority review status to Adapt Pharma's opioid overdose treatment
Adapt Pharma's NARCAN Nasal Spray, or naloxone hydrochloride, has received priority review status from the FDA as an emergency medication for patients who are suffering from opioid overdose. The spray will be the first noninjectable opioid treatment in the US if it receives approval from the FDA. Seeking Alpha (free registration) (9/24)
Share: LinkedInTwitterFacebookGoogle+Email
NeuroMetrix app boosts pain management in Quell device users
An Android application that can be used with the Quell wearable pain relief device was designed by NeuroMetrix. The app allows Quell users to track their sleep and the treatment they are receiving. Clinical trial data showed the app helped improve pain management and cut pain medications use in more than 80% of participants. (9/29)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
Policy & Trends
Maine collects tons of unused opioid medications
Maine officials said an unused prescription drug collection program held over the past weekend brought in 19,760 pounds of unwanted or expired medications. Most of the state's police stations have collection bins. WCSH-TV (Portland, Maine) (9/29)
Share: LinkedInTwitterFacebookGoogle+Email
Other News
APS News
Nominate your APS leaders!
The APS Nominating Committee solicits your nominations to elect the 2016-2017 Board of Directors and Nominating Committee. Nominees must be APS members and should demonstrate leadership qualities, have the ability to develop, communicate and sustain the Society’s vision, possess strategic thinking and communications skills, and have a strong dedication to the society, its members, and the purposes APS serves. The deadline to nominate is Friday, Oct. 23. Learn more.
Share: LinkedInTwitterFacebookGoogle+Email
Clinical Centers of Excellence Award Program -- Now open
The APS Clinical Centers of Excellence (CCOE) award program helps advance the quality of pain management in the US by recognizing and rewarding excellence in quality clinical care. Any US-based, multidisciplinary, clinical program that provides direct patient care and is primarily focused on the treatment of pain and meet the award criteria are encouraged to apply. Selection of awardees will be based on the quality of services provided and not size of program. This distinction is one of APS's highest honors in the area of clinical treatment. Applications are open through Nov. 30! Learn more.
Share: LinkedInTwitterFacebookGoogle+Email
Knowledge is power. Power to do evil ... or power to do good. Power itself is not evil. So knowledge itself is not evil."
-- Veronica Roth,
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about APS ->Membership | Annual Meeting | Education | Funding Opportunities | About Us
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Advertising:  Wynn Hansen
  P: 202.470.1149
Editor:  Tom Parks

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information